Core Outcome Measure for Life Participation in Patients with CKD: Standardized Outcomes in Nephrology Workshops Report.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hughes Anastasia, Matus Gonzalez Andrea, Amir Noa, Arancibia Garcia Macarena, Caskey Fergus J, Cervantes Lilia, Cho Yeoungjee, Cazzolli Rosanna, Dobrijevic Ellen, Elliott Meghan J, Farragher Janine, Ferreiro Alejandro, Greenwood Sharlene, Guha Chandana, Howell Martin, Huuskes Brooke M, Lampo Mauro, Levin Adeera, Lorca Eduardo, Malvar Ana, Manera Karine, Mascheroni Claudio A, Mellado Haydee, Molina Soledad, Monkowski Matias, Recabarren Silva Javier, Sautenet Bénédicte, Scholes-Robertson Nicole, Sepulveda Alejandro, Sluiter Amanda, Sola Laura, Teixeira-Pinto Armando, Trimarchi Herman, van Zwieten Anita, Gutiérrez Ventura Jorge, Viecelli Andrea K, Wang Bill, Weng Linda, Wong Germaine, Wu Rebecca, Jaure Allison, SONG-CKD Life Participation Workshop Investigators
Аннотация
BACKGROUND: Life participation is of critical importance to patients with CKD not requiring KRT, their caregivers, and health professionals. However, life participation is rarely and inconsistently assessed in trials in CKD. The aim was to establish a core outcome measure for life participation in patients with CKD not requiring KRT.
METHODS: An online (English language) and an in-person (Spanish language) consensus workshop, 1 hour in length, were held in March and April 2024, respectively, and were held to discuss and establish a meaningful, relevant, and feasible core patient-reported outcome measure for life participation for trials in CKD. Transcripts were analyzed thematically.
RESULTS: Workshops included 130 participants, including 74 patients and caregivers, and 56 health professionals, from 18 countries. Four themes were identified. Enabling interpretation within individual contexts and circumstances included considering relevance to patients' own priorities, capturing key life activities common to all patients, reflecting the goal of leading a fulfilling life, acknowledging the variability and multiplicity of domains, and facilitating linguistic and cultural translation. Having broad clinical relevance across CKD meant covering the spectrum of CKD stages and diagnoses and allowing comparison across treatment stages. Supporting widespread implementation entailed minimizing burden of administration and completion, establishing psychometric robustness, seeking endorsement to legitimize the measure, and ensuring accessibility and acceptability across different settings. Highlighting opportunities to address life participation captured promoting person-centered clinical care and generating ideas for novel interventions to improve life participation.
CONCLUSIONS: A core outcome measure for life participation in patients with CKD should enable a patient to interpret life participation in their own context, have applicability across the CKD population, and be psychometrically robust and feasible to implement. Measuring life participation in a consistent and meaningful way across trials can better support patient-centered decision making and outcomes.